OM1 broadens its Mental Health and Neuroscience Real-World Data Network with datasets for schizophrenia and bipolar disorder

OM1 has announced the development of new real-world datasets from 148,000 people with schizophrenia and bipolar disorder for its Mental Health and Neuroscience Real-World Data Network to empower clinical research and improve patient outcomes.

OM1, a US leading real-world data (RWD) outcomes and technology company, is adding real-world datasets for schizophrenia and bipolar disorder to its established Mental Health and Neuroscience Real-World Data Network. Using unique artificial intelligence and machine learning (AI/ML) modelling capabilities, OM1 will extract and enhance longitudinal clinical data from more than 148,000 people with schizophrenia and bipolar disorder, with the aim of facilitating improved personalized treatment options and outcomes for patients.

OM1 is spearheading advancement of RWD and real-world evidence (RWE) for clinical research by developing large, electronically connected networks of health data from demographically and geographically diverse populations in numerous specialties including immunology, cardiometabolic, mental health, neuroscience, respiratory, and ear, nose and throat specialties. They deploy unique AI/ML modelling capabilities to measure and predict outcomes and accelerate medical research in order to lead to actionable insights based on a deeper understanding of patients and conditions.

The established OM1 Mental Health and Neuroscience Real-World Data Network is already based on more than 3 million patients. The company is able harness RWD from clinical notes from its mental health network of more than 9,000 clinicians working in 2,500 clinics across all 50 states. In the US, 2.8% of the population have bipolar disorder and the prevalence of schizophrenia among adults is estimated to be 1.5 million people per year.

“With increased clinical development and new medications coming to market, it’s imperative to understand how these treatments are working across patients in the real world,” said Carl Marci, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. “Using our vast Mental Health and Neuroscience Network with deep clinical data allows for optimal and personalized treatment plans for patients, ultimately driving improved care and outcomes.”

The Mental Health and Neuroscience Real-World Data Network is planned to further expand to include anxiety disorders in the coming months.